 Shares of Oramed Pharmaceuticals Inc. ORMP plunged 72 in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Orameds treatment to placebo to see if it improved glycemic control ... The post : Orameds oral insulin pill fails; stock is down 72 appeared first on ForexTV... 